Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (9989.HK)
HKD 4.46
(0.22%)
HKD 4.46
(0.22%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 5.56 Billion CNY | -13.94% |
| 2022 | 6.46 Billion CNY | 14.32% |
| 2021 | 5.65 Billion CNY | 0.16% |
| 2020 | 5.64 Billion CNY | -10.35% |
| 2019 | 6.29 Billion CNY | 28.08% |
| 2018 | 4.91 Billion CNY | 4.48% |
| 2017 | 4.7 Billion CNY | 21.1% |
| 2016 | 3.88 Billion CNY | 58.62% |
| 2015 | 2.44 Billion CNY | 143.04% |
| 2014 | 1 Billion CNY | 0.0% |
| 2013 | - CNY | -100.0% |
| 2012 | 73.16 Million CNY | 0.0% |
| 2011 | - CNY | 0.0% |
| 2010 | - CNY | -100.0% |
| 2009 | 244 Million CNY | 22.97% |
| 2008 | 198.41 Million CNY | 148.02% |
| 2007 | 80 Million CNY | -63.3% |
| 2006 | 218 Million CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 4.59 Billion CNY | -35.33% |
| 2024 Q1 | 4.94 Billion CNY | -11.11% |
| 2023 Q4 | 5.56 Billion CNY | -5.89% |
| 2023 FY | 5.56 Billion CNY | -13.94% |
| 2023 Q1 | 6.31 Billion CNY | -2.27% |
| 2023 Q2 | 6.21 Billion CNY | -1.65% |
| 2023 Q3 | 5.91 Billion CNY | -4.86% |
| 2022 Q3 | 6.98 Billion CNY | -1.45% |
| 2022 FY | 6.46 Billion CNY | 14.32% |
| 2022 Q1 | 6.33 Billion CNY | 12.1% |
| 2022 Q4 | 6.46 Billion CNY | -7.52% |
| 2022 Q2 | 7.09 Billion CNY | 11.88% |
| 2021 Q3 | 5.53 Billion CNY | 7.8% |
| 2021 Q1 | 5.76 Billion CNY | 2.09% |
| 2021 Q2 | 5.13 Billion CNY | -10.97% |
| 2021 FY | 5.65 Billion CNY | 0.16% |
| 2021 Q4 | 5.65 Billion CNY | 2.23% |
| 2020 FY | 5.64 Billion CNY | -10.35% |
| 2020 Q3 | 5.64 Billion CNY | -18.31% |
| 2020 Q4 | 5.64 Billion CNY | 0.09% |
| 2020 Q2 | 6.9 Billion CNY | 5.22% |
| 2020 Q1 | 6.56 Billion CNY | 4.22% |
| 2019 Q3 | 6.34 Billion CNY | 7.04% |
| 2019 Q4 | 6.29 Billion CNY | -0.83% |
| 2019 Q1 | 4.2 Billion CNY | -14.42% |
| 2019 Q2 | 5.93 Billion CNY | 41.0% |
| 2019 FY | 6.29 Billion CNY | 28.08% |
| 2018 Q4 | 4.91 Billion CNY | -4.22% |
| 2018 FY | 4.91 Billion CNY | 4.48% |
| 2018 Q3 | 5.13 Billion CNY | 11.57% |
| 2018 Q2 | 4.6 Billion CNY | -2.94% |
| 2018 Q1 | 4.73 Billion CNY | 0.73% |
| 2017 Q4 | 4.7 Billion CNY | 3.82% |
| 2017 FY | 4.7 Billion CNY | 21.1% |
| 2017 Q3 | 4.53 Billion CNY | 14.46% |
| 2017 Q2 | 3.95 Billion CNY | 2.49% |
| 2017 Q1 | 3.86 Billion CNY | -0.57% |
| 2016 Q1 | 2.33 Billion CNY | -4.48% |
| 2016 FY | 3.88 Billion CNY | 58.62% |
| 2016 Q3 | 2.75 Billion CNY | 15.56% |
| 2016 Q4 | 3.88 Billion CNY | 41.08% |
| 2016 Q2 | 2.38 Billion CNY | 1.87% |
| 2015 Q2 | 1.17 Billion CNY | -1.42% |
| 2015 Q1 | 1.18 Billion CNY | 17.98% |
| 2015 Q3 | 2.6 Billion CNY | 121.9% |
| 2015 FY | 2.44 Billion CNY | 143.04% |
| 2015 Q4 | 2.44 Billion CNY | -5.83% |
| 2014 Q3 | 1.01 Billion CNY | -6.19% |
| 2014 Q2 | 1.08 Billion CNY | 0.0% |
| 2014 Q1 | - CNY | 0.0% |
| 2014 Q4 | 1 Billion CNY | -0.82% |
| 2014 FY | 1 Billion CNY | 0.0% |
| 2013 Q3 | - CNY | 0.0% |
| 2013 Q4 | - CNY | 0.0% |
| 2013 Q1 | - CNY | -100.0% |
| 2013 FY | - CNY | -100.0% |
| 2013 Q2 | - CNY | 0.0% |
| 2012 FY | 73.16 Million CNY | 0.0% |
| 2012 Q4 | 73.16 Million CNY | 0.0% |
| 2012 Q3 | - CNY | 0.0% |
| 2012 Q2 | - CNY | 0.0% |
| 2012 Q1 | - CNY | 0.0% |
| 2011 FY | - CNY | 0.0% |
| 2011 Q2 | - CNY | 0.0% |
| 2011 Q3 | - CNY | 0.0% |
| 2011 Q4 | - CNY | 0.0% |
| 2011 Q1 | - CNY | 0.0% |
| 2010 Q1 | 244 Million CNY | 0.0% |
| 2010 FY | - CNY | -100.0% |
| 2010 Q4 | - CNY | 0.0% |
| 2010 Q3 | - CNY | -100.0% |
| 2010 Q2 | 52 Million CNY | -78.69% |
| 2009 FY | 244 Million CNY | 22.97% |
| 2009 Q2 | 146.66 Million CNY | 0.0% |
| 2009 Q4 | 244 Million CNY | 0.0% |
| 2008 FY | 198.41 Million CNY | 148.02% |
| 2007 FY | 80 Million CNY | -63.3% |
| 2006 FY | 218 Million CNY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 6.8 Million HKD | -81586.004% |
| Grand Pharmaceutical Group Limited | 3.4 Billion HKD | -63.409% |
| Extrawell Pharmaceutical Holdings Limited | 120.41 Million HKD | -4519.895% |
| Wai Yuen Tong Medicine Holdings Limited | 460.94 Million HKD | -1106.818% |
| Qianhai Health Holdings Limited | 487 Thousand HKD | -1142162.02% |
| Lee's Pharmaceutical Holdings Limited | 204.14 Million HKD | -2625.001% |
| Essex Bio-Technology Limited | 294.02 Million HKD | -1791.971% |
| Tongfang Kontafarma Holdings Limited | 333.82 Million HKD | -1566.397% |
| PuraPharm Corporation Limited | 424.77 Million HKD | -1209.607% |
| SSY Group Limited | 3.37 Billion HKD | -64.869% |
| JBM (Healthcare) Limited | 133.4 Million HKD | -4069.808% |
| Jacobson Pharma Corporation Limited | 749.37 Million HKD | -642.323% |
| China Resources Pharmaceutical Group Limited | 85.84 Billion HKD | 93.52% |